Unknown

Dataset Information

0

Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models.

ABSTRACT: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The NLRP3 inflammasome is a multi-protein complex responsible for the processing of the proinflammatory cytokine interleukin-1? and is implicated in many inflammatory diseases. Here we show that several clinically approved and widely used NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3 inflammasome via inhibition of the volume-regulated anion channel in macrophages, independently of COX enzymes. Flufenamic acid and mefenamic acid are efficacious in NLRP3-dependent rodent models of inflammation in air pouch and peritoneum. We also show therapeutic effects of fenamates using a model of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer's disease. These data suggest that fenamate NSAIDs could be repurposed as NLRP3 inflammasome inhibitors and Alzheimer's disease therapeutics.

SUBMITTER: Daniels MJ 

PROVIDER: S-EPMC4987536 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The NLRP3 inflammasome is a multi-protein complex responsible for the processing of the proinflammatory cytokine interleukin-1β and is implicated in many inflammatory diseases. Here we show that several clinically approved and widely used NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3 inflammasome via inhibition of the volume-regulated anion channel in macrophages,  ...[more]

Similar Datasets

Unknown The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease.
| S-EPMC7530640 | biostudies-literature
Unknown Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease.
| S-EPMC8623160 | biostudies-literature
Transcriptomics Effects of BDNF in Rodent Models of Aging and Alzheimer's Disease
2009-01-30 | GSE14522 | GEO
Unknown Qiliqiangxin Modulates the Gut Microbiota and NLRP3 Inflammasome to Protect Against Ventricular Remodeling in Heart Failure.
| S-EPMC9201726 | biostudies-literature
Unknown Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.
| S-EPMC5641232 | biostudies-literature
Unknown Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models.
| S-EPMC8399941 | biostudies-literature
Unknown TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.
| S-EPMC7190872 | biostudies-literature
Unknown Concurrent suppression of Aβ aggregation and NLRP3 inflammasome activation for treating Alzheimer's disease.
| S-EPMC8905858 | biostudies-literature
Unknown Hippocampal Deficits in Amyloid-?-Related Rodent Models of Alzheimer's Disease.
| S-EPMC7154147 | biostudies-literature
Unknown VEGF-A-related genetic variants protect against Alzheimer's disease.
| S-EPMC9004571 | biostudies-literature